Comparative efficacy and safety of intra-nasal dexmedetomidine and oral midazolam as pre medication in children undergoing minor elective surgical procedures: Results of a randomized, double blind trial

2019 ◽  
Vol 12 (1) ◽  
pp. 48-54
Author(s):  
Shilpi Yadav ◽  
◽  
Vikram Vardhan ◽  
Poonam Sangamlal Gupta ◽  
EK Ramdas ◽  
...  
Keyword(s):  
Surgical Procedures ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Comparative Efficacy ◽  
Double Blind ◽  
Blind Trial ◽  
Elective Surgical Procedures ◽  
Oral Midazolam

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

2008 ◽  
Vol 26 (3) ◽  
pp. 589-599 ◽  
Author(s):  
Karl Andersen ◽  
Myron H Weinberger ◽  
Brent Egan ◽  
Christian M Constance ◽  
Mohammed A Ali ◽  
...  
Keyword(s):  
Renin Inhibitor ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Comparative Efficacy ◽  
Double Blind ◽  
Blind Trial ◽  
Direct Renin Inhibitor

S601 EFFICACY AND SAFETY OF A SUBCUTANEOUS DICLOFENAC FORMULATION IN THE MANAGEMENT OF ACUTE PAIN: A RANDOMISED, DOUBLE-BLIND TRIAL

2011 ◽  
Vol 5 (S1) ◽  
pp. 269-270
Author(s):  
T. Dietrich ◽  
R. Leeson ◽  
B. Zielińska-Kaźmierska ◽  
M. Opadczuk ◽  
E. Kozieł ◽  
...  
Keyword(s):  
Acute Pain ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Blind Trial

Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients

1997 ◽  
Vol 171 (1) ◽  
pp. 73-77 ◽  
Author(s):  
I. Pelc ◽  
P. Verbanck ◽  
O. Le Bon ◽  
M. Gavrilovic ◽  
K. Lion ◽  
...  
Keyword(s):  
Animal Models ◽  
Alcohol Drinking ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Blind Trial ◽  
Efficacy Parameters ◽  
Clinical Conditions ◽  
Alcohol Dependent

BackgroundAcamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions.MethodIn order to assess the efficacy and safety of the drug in the treatment of detoxified alcoholics, we performed a 90-day double-blind trial comparing two dosages of acamprosate (1332 mg/day and 1998 mg/day).ResultsFor all efficacy parameters, acamprosate appeared to be significantly superior to placebo, with a trend towards a better effect at the higher dosage. Furthermore, acamprosate appeared to be extremely safe.ConclusionThis study confirms that acamprosate could be an interesting adjuvant for maintaining abstinence in detoxified alcoholics.

Sign in / Sign up

Export Citation Format

Share Document